Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 3/20 | 0.52 |
| ▸ | ATP4B | P51164 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 13/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 13/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 13/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 13/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 13/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 13/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417678 | 0.76 | CSNK1E (0.62) | ATP4AATP4BCYP1A2MEN1KMT2A | |
| SCHEMBL12306384 | 0.75 | AKT1 (0.41) | CYP1A2MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL8816284 | 0.75 | ATP4A (0.74) | ATP4AATP4BCYP1A2MEN1KMT2A | |
| SCHEMBL5739027 | 0.74 | SMN1; SMN2 (0.45) | CYP1A2MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL5417170 | 0.73 | HRH3 (0.63) | ATP4AATP4BMEN1KMT2APSEN1 | |
| SCHEMBL9746607 | 0.73 | ATP4A (0.58) | ATP4AATP4BCYP1A2MEN1KMT2A | |
| SCHEMBL14561029 | 0.72 | MAPK9 (0.57) | MAPK1 | |
| Iodide SCHEMBL9746994 | 0.72 | ATP4A (0.57) | ATP4AATP4BCYP1A2MEN1KMT2A | |
| SCHEMBL31444130 | 0.71 | ATP4A (0.54) | ATP4AATP4BCYP1A2MEN1KMT2A | |
| SCHEMBL6940664 | 0.71 | ATP4A (0.72) | ATP4AATP4BCYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186714-B2 | Imidazo[1,2-α]pyridine derivatives for the prophylaxis and treatment of herpes viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1401836-B1 | IMIDAZO¬1,2-A|PYRIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF HERPES VIRAL INFECTIONS | SMITHKLINE BEECHAM CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060167252-A1 | Imidazo[1,2-a]pyridine derivatives for treatment of herpes viral infections | GUDMUNDSSON KRISTJAN | 2006-07-27 | — | — | US | disclosed |
| US-20050228004-A1 | Imidazo'1,2-a!pyridine derivatives for the prophylaxis and treatment of herpes viral infections | SMITHKLINE BEECHAM CORPORATION | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228004-A1 | Imidazo'1,2-a!pyridine derivatives for the prophylaxis and treatment of herpes viral infections | TPMT, IRF3, ZC3HAV1 | ATP4A 886/4885ATP4B 1899/4885CYP1A2 116/4885 |
| US-20060167252-A1 | Imidazo[1,2-a]pyridine derivatives for treatment of herpes viral infections | IRF3, IFNAR1, IL2 | ATP4A 897/4885ATP4B 1765/4885CYP1A2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.